Literature DB >> 30325561

Surgical treatment of medication-related osteonecrosis of the upper jaw: Case series.

Suad Aljohani1,2, Matthias Troeltzsch1, Sigurd Hafner1, Gabriele Kaeppler3, Gerson Mast1, Sven Otto1.   

Abstract

PURPOSE: The management of maxillary medication-related osteonecrosis of the jaw (MRONJ) is challenging. Therefore, identifying the proper treatment is important. This study aimed to evaluate the surgical treatment of maxillary MRONJ using single-layer closure with mucoperiosteal flap and double-layer closure with buccal fat pad flap (BFPF) and mucoperiosteal flap and to find the outcomes after rehabilitation with obturators.
METHODS: A retrospective analysis was conducted and included all surgically treated and followed-up maxillary MRONJ cases in a single center. Demographics and clinical data, stage of MRONJ, surgical treatment, and treatment outcome were collected.
RESULTS: Seventy-nine lesions were included. Removal of necrotic bone was followed by coverage with mucoperiosteal flap in 60 lesions and BFPF in 14 lesions. Seven lesions (five primarily and two following unsuccessful treatment with BFPF) underwent necrectomy and were reconstructed with obturators. Complete mucosal healing was achieved in 76.7% of the lesions covered with mucoperiosteal flap. BFPF led to complete mucosal healing in 85.7% of the lesions. No complications were observed in the defects rehabilitated with obturators.
CONCLUSION: Removal of necrotic bone followed by closure with mucoperiosteal flap is reliable for MRONJ treatment. BFPF is effective for closure of MRONJ-related oroantral communications (OACs).
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. All rights reserved.

Entities:  

Keywords:  jaw osteonecrosis; maxilla; medication-related osteonecrosis of the jaw; osteonecrosis of the jaw

Mesh:

Substances:

Year:  2018        PMID: 30325561     DOI: 10.1111/odi.12992

Source DB:  PubMed          Journal:  Oral Dis        ISSN: 1354-523X            Impact factor:   3.511


  6 in total

1.  Surgical treatment of 61 consecutive patients with maxillary stage 3 medication-related osteonecrosis of the jaws using a pedicled buccal fat pad.

Authors:  Sanne Werner Moeller Andersen; Ditte Gertz Mogensen; Morten Schioedt; Thomas Kofod
Journal:  Oral Maxillofac Surg       Date:  2022-04-01

2.  The Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ): A Systematic Review with a Pooled Analysis of Only Surgery versus Combined Protocols.

Authors:  Olga Di Fede; Federica Canepa; Vera Panzarella; Rodolfo Mauceri; Carmine Del Gaizo; Alberto Bedogni; Vittorio Fusco; Pietro Tozzo; Giuseppe Pizzo; Giuseppina Campisi; Antonio Galvano
Journal:  Int J Environ Res Public Health       Date:  2021-08-10       Impact factor: 3.390

3.  Differences between auto-fluorescence and tetracycline-fluorescence in medication-related osteonecrosis of the jaw-a preclinical proof of concept study in the mini-pig.

Authors:  Oliver Ristow; Dirk Nehrbass; Stephan Zeiter; Daniel Arens; Julius Moratin; Christoph Pautke; Jürgen Hoffmann; Christian Freudlsperger; Sven Otto
Journal:  Clin Oral Investig       Date:  2020-05-22       Impact factor: 3.573

4.  Use and Evaluation of a Computer-Assisted Examination Method for the Diagnosis and Analysis of Medication-Related Osteonecrosis of the Jaw.

Authors:  Max Wilkat; Daman Deep Singh; Isabelle Lutz; Henriette Möllmann; Nils-Claudius Gellrich; Majeed Rana
Journal:  Craniomaxillofac Trauma Reconstr       Date:  2020-07-15

Review 5.  Infection as an Important Factor in Medication-Related Osteonecrosis of the Jaw (MRONJ).

Authors:  Sven Otto; Suad Aljohani; Riham Fliefel; Sara Ecke; Oliver Ristow; Egon Burian; Matthias Troeltzsch; Christoph Pautke; Michael Ehrenfeld
Journal:  Medicina (Kaunas)       Date:  2021-05-09       Impact factor: 2.430

6.  Combined approach to treatment of advanced stages of medication-related osteonecrosis of the jaw patients.

Authors:  Onur Şahin; Ender Akan; Birkan Tatar; Ceren Ekmekcioğlu; Nuri Ünal; Onur Odabaşı
Journal:  Braz J Otorhinolaryngol       Date:  2021-05-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.